Kairos Pharma, Ltd.
KAPA
$1.20
-$0.03-2.44%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 960.00K | 773.00K | 1.27M | 369.00K | 159.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.46M | 1.27M | 1.45M | 383.00K | 222.00K |
| Operating Income | -1.46M | -1.27M | -1.45M | -383.00K | -222.00K |
| Income Before Tax | -1.42M | -1.26M | -980.00K | -1.05M | -253.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.42M | -1.26M | -980.00K | -1.05M | -253.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.42M | -1.26M | -980.00K | -1.05M | -253.00K |
| EBIT | -1.46M | -1.27M | -1.45M | -383.00K | -222.00K |
| EBITDA | -1.42M | -1.23M | -1.41M | -343.00K | -182.00K |
| EPS Basic | -0.08 | -0.08 | -0.07 | -0.10 | -0.02 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.07 | -0.06 | -0.02 |
| EPS Diluted | -0.08 | -0.08 | -0.07 | -0.10 | -0.02 |
| Normalized Diluted EPS | -0.05 | -0.05 | -0.07 | -0.06 | -0.02 |
| Average Basic Shares Outstanding | 17.21M | 15.88M | 13.39M | 10.91M | 10.56M |
| Average Diluted Shares Outstanding | 17.21M | 15.88M | 13.39M | 10.91M | 10.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |